EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®. Caris, a U.S.-based leader in next-generation AI TechBio and precision medicine, will collaborate with EDX Medical to advance their diagnostic solutions.
Under the agreement, EDX Medical and Caris Life Sciences will collaborate exclusively in the UK and Nordic countries for at least three years, distributing Caris’ advanced molecular profiling services for both clinical and research uses.
Caris’ cutting-edge molecular profiling, combined with proprietary artificial intelligence, helps physicians make more precise and personalized cancer treatment decisions. This comprehensive approach analyzes DNA, RNA, and proteins to provide a detailed molecular blueprint for identifying tailored treatment options. Caris boasts one of the world’s largest cancer analysis platforms, offering advanced tumor profiling, including whole exome and whole transcriptome sequencing of over 23,000 genes. This analysis of tumor biomarkers assists healthcare providers in making informed treatment decisions.
Caris’ solid tumor and liquid biopsy (blood) molecular profiling services, along with its AI solutions, will be exclusively available through EDX Medical in the UK, Sweden, Denmark, Norway, and Finland, with potential expansions to other regions and products.
Professor Sir Chris Evans, OBE, Founder of EDX Medical, commented: “This agreement is a significant milestone in our strategy to offer world-class diagnostic tools and services that can transform disease detection, treatment, and patient outcomes. Given the rapid pace of scientific advancement, using comprehensive analysis rather than limited gene selection is crucial for cancer patients needing timely, optimal treatment. Caris is an ideal partner in this endeavor.”
Dr. Mike Hudson, CEO of EDX Medical, added: “Both EDX Medical and Caris are at the forefront of providing clinicians with essential biological information from human samples. We are honored to be chosen by Caris to jointly offer these valuable cancer tumor profiling services in the UK and key European regions.”
Dr. David Spetzler, President of Caris Life Sciences, stated: “We are excited to partner with EDX Medical to distribute our molecular profiling services in the UK and Nordic countries. This collaboration supports Caris’ mission to enable physicians worldwide to make the most personalized treatment decisions and improve patient outcomes.”
About EDX Medical Group
EDX Medical Group plc is listed on the Apex segment of the AQSE Growth Market (TIDM: EDX). The company operates facilities in Cambridge and Oxford, UK, and provides a range of innovative clinical diagnostic products and services.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and a pioneer in precision medicine, dedicated to revolutionizing healthcare and enhancing quality of life. Headquartered in Irving, Texas, with offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland, Caris offers its services globally.
